Oncologist: Combination therapy of cetuximab + irinotecan + bevacizumab fails to improve PFS but improves OS in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)

Irinotecan in combination with cetuximab approved for irinotecan-refractory metastatic diseaseColorectal cancer (mCRC)

Irinotecan in combination with cetuximab approved for irinotecan-refractory metastatic diseaseColorectal cancer (mCRC)

This is a multicenter, randomized, double-blind, placebo-controlled phase II trial of irinotecan-refractory metastatic colorectal cancer (mCRC) previously untreated with anti-EGFR therapy

This is a multicenter, randomized, double-blind, placebo-controlled phase II trial of irinotecan-refractory metastatic colorectal cancer (mCRC) previously untreated with anti-EGFR therapy

Due to a change in funding, the study ended prematurely after 36 patients completed out of a planned enrollment of 120 patients

Due to a change in funding, the study ended prematurely after 36 patients completed out of a planned enrollment of 120 patients

The median PFS for CBI and CI was 9.

The median PFS for CBI and CI was 9.

The ORR was 36.

The ORR was 36.

There was no significant difference in the incidence of grade 1 and 2 AEs between the two groups

In conclusion, the study shows that CBI combined therapy cannot improve the PFS of patients, but improves the OS of patients, which is worthy of further exploration in the future

Original source:

Marla Lipsyc-Sharf1 , Fang-Shu Ou , Matthew B.

Marla Lipsyc-Sharf1 , Fang-Shu Ou , Matthew B.
Yurgelun, et al.
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
The Oncologist, 2022, XX, 1 –7 .
https://doi.
org/10.
1093/oncolo/oyab025.
 

Leave a comment here